PHR Stock Chart & Stats
zł3.08
zł0.00(0.00%)
At close: 4:00 PM EDT
zł3.08
zł0.00(0.00%)
Day’s Range― - ―
52-Week Rangezł2.50 - zł4.32
Previous CloseN/A
Volume591.00
Average Volume (3M)4.49K
Market Cap
zł36.31M
Enterprise Valuezł34.98
Total Cash (Recent Filing)zł421.00K
Total Debt (Recent Filing)zł314.00K
Price to Earnings (P/E)―
Beta0.36
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield72.62%
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,137,758
10 Day Avg. Volume6,545
30 Day Avg. Volume4,487
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.00
Price to Sales (P/S)18.36
P/FCF Ratio-9.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PHR FAQ
What was Pharmena S.A.’s price range in the past 12 months?
Pharmena S.A. lowest stock price was zł2.50 and its highest was zł4.32 in the past 12 months.
What is Pharmena S.A.’s market cap?
Pharmena S.A.’s market cap is zł36.31M.
When is Pharmena S.A.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pharmena S.A.’s earnings last quarter?
Currently, no data Available
Is Pharmena S.A. overvalued?
According to Wall Street analysts Pharmena S.A.’s price is currently Overvalued.
Does Pharmena S.A. pay dividends?
Pharmena S.A. pays a Notavailable dividend of zł2.36 which represents an annual dividend yield of 72.62%. See more information on Pharmena S.A. dividends here
What is Pharmena S.A.’s EPS estimate?
Pharmena S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmena S.A. have?
Pharmena S.A. has 11,137,758 shares outstanding.
What happened to Pharmena S.A.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pharmena S.A.?
Currently, no hedge funds are holding shares in PL:PHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharmena S.A.
Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. It also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, the company is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. operates as a subsidiary of Pelion S.A.